Literature DB >> 26670318

Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation.

Yong Seek Kim1, Ji Soo Song2,3, Hyun Kyung Lee1,4, Young Min Han1,4.   

Abstract

PURPOSE: To evaluate the long-term outcomes and imaging features associated with hypervascularization of hypovascular nodules that show T2 iso-/hypointensity and hypointensity on hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance (MR) images in patients with chronic liver disease.
MATERIALS AND METHODS: Sixty patients and 114 nodules, which were hypovascular and iso-/hypointense on T2-weighted images and hypointense on HBP of gadoxetic acid-enhanced MRI, were included. We evaluated the effect of baseline clinical features, baseline MR features and growth rate on subsequent hypervascularization.
RESULTS: Twenty-seven nodules in 21 patients transformed to hypervascular hepatocellular carcinoma (HCC). Using multivariate Cox analysis, T1 hyperintensity (hazard ratio [HR] = 2.69, P = 0.021), previous history of HCC (HR = 2.64, P = 0.021), and initial nodule size (HR = 1.09, P = 0.046) were identified to be associated with hypervascularization. The growth rate of nodules was a more powerful determinant of subsequent hypervascularization than baseline clinical and MR features. At long-term follow-up after >3 years, only one nodule with T1 isointensity showed hypervascularization.
CONCLUSION: Careful follow-up or diagnostic procedures, such as biopsy, should be considered for up to 3 years after detection of hypointense nodules on HBP with T1 hyperintensity or a higher growth rate. KEY POINTS: • T1 hyperintensity is a baseline MR predictive factor for subsequent hypervascularization. • A higher growth rate is a more powerful determinant of subsequent hypervascularization. • Management of patients with these predictive factors requires more attention.

Entities:  

Keywords:  Gadoxetic acid; Hepatocarcinogenesis; Hepatocellular carcinoma; Hypervascular transformation; Magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26670318     DOI: 10.1007/s00330-015-4146-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation.

Authors:  T Kim; R L Baron; M A Nalesnik
Journal:  AJR Am J Roentgenol       Date:  2000-10       Impact factor: 3.959

2.  Natural course of hypovascular nodules detected on gadoxetic acid-enhanced MR imaging: presence of fat is a risk factor for hypervascularization.

Authors:  Dai Joishi; Akihisa Ueno; Akihiro Tanimoto; Shigeo Okuda; Yohei Masugi; Katsura Emoto; Kiyoshi Okuma; Michiie Sakamoto; Yutaka Imai; Sachio Kuribayashi
Journal:  Magn Reson Med Sci       Date:  2013-10-29       Impact factor: 2.471

3.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

4.  Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver.

Authors:  Riccardo Inchingolo; Anna Maria De Gaetano; Davide Curione; Marzia Ciresa; Luca Miele; Maurizio Pompili; Fabio Maria Vecchio; Felice Giuliante; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2014-11-28       Impact factor: 5.315

5.  Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.

Authors:  Peng-Ju Xu; Fu-Hua Yan; Jian-Hua Wang; Yan Shan; Yuan Ji; Cai-Zhong Chen
Journal:  J Comput Assist Tomogr       Date:  2010-07       Impact factor: 1.826

6.  Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.

Authors:  Hiroki Haradome; Luigi Grazioli; Rita Tinti; Mario Morone; Utaroh Motosugi; Katsuhiro Sano; Tomoaki Ichikawa; Thomas C Kwee; Stefano Colagrande
Journal:  J Magn Reson Imaging       Date:  2011-05-19       Impact factor: 4.813

7.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

8.  Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma.

Authors:  Satoshi Kobayashi; Osamu Matsui; Toshifumi Gabata; Wataru Koda; Tetsuya Minami; Yasuji Ryu; Kazuto Kozaka; Azusa Kitao
Journal:  Eur J Radiol       Date:  2012-06-29       Impact factor: 3.528

Review 9.  Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features.

Authors:  Robert F Hanna; Diego A Aguirre; Norbert Kased; Shawn C Emery; Michael R Peterson; Claude B Sirlin
Journal:  Radiographics       Date:  2008 May-Jun       Impact factor: 5.333

Review 10.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

View more
  7 in total

1.  Feasibility of self-gated isotropic radial late-phase MR imaging of the liver.

Authors:  Jakob Weiss; Jana Taron; Ahmed E Othman; Robert Grimm; Matthias Kuendel; Petros Martirosian; Christer Ruff; Christina Schraml; Konstantin Nikolaou; Mike Notohamiprodjo
Journal:  Eur Radiol       Date:  2016-06-08       Impact factor: 5.315

2.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

3.  Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.

Authors:  Wei Zhang; Hui Juan Chen; Zhen J Wang; Wei Huang; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2016-08-03       Impact factor: 5.315

4.  Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Sangwon Han; Chong Hyun Suh; Richard Kinh Gian Do; Jeong Min Lee
Journal:  Acad Radiol       Date:  2020-09-20       Impact factor: 5.482

Review 5.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

6.  Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.

Authors:  Nai-Chi Chiu; Chien-Wei Su; Chien-An Liu; Yi-Hsiang Huang; Yi-You Chiou
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

7.  Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification.

Authors:  Francesco Vasuri; Matteo Renzulli; Silvia Fittipaldi; Stefano Brocchi; Alfredo Clemente; Salvatore Cappabianca; Luigi Bolondi; Rita Golfieri; Antonietta D'Errico
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.